# Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

> **NCT01086540** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 57 (actual)

## Conditions studied

- Systemic Sclerosis-Associated PAH

## Interventions

- **BIOLOGICAL:** Rituximab
- **OTHER:** Placebo
- **DIAGNOSTIC_TEST:** CMRI
- **DRUG:** prednisone
- **DRUG:** methylprednisolone
- **DRUG:** diphenhydramine
- **DRUG:** acetaminophen

## Key facts

- **NCT ID:** NCT01086540
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-24
- **Primary completion:** 2018-06-05
- **Final completion:** 2019-12-15
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01086540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01086540, "Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01086540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*